News EXACT Therapeutics

Stocks

EXTX

NO0010852213

Biotechnology & Medical Research

Real-time Oslo Bors 06:54:20 2026-09-25 EDT			5-day change	1st Jan Change
0.7050 ^NOK	-11.88%		-10.19%	-48.91%

09-03	EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-30	Exact Therapeutics to Delist from Euronext Growth Oslo in October	MT

All News

Mentions Relevance

09-04	EXACT Therapeutics publishes shareholder information regarding the delisting	AQ
09-03	EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09-03	EXACT Therapeutics first half 2026 interim report	AQ
08-31	EXACT Therapeutics AS - Issuance of share options	AQ
07-02	EXACT Therapeutics : Oslo Stock Exchange approves application to delist EXACT Therapeutics’ shares	PU
06-30	Exact Therapeutics to Delist from Euronext Growth Oslo in October	MT
06-30	EXACT Therapeutics AS - Removal from trading	AQ
06-26	EXACT Therapeutics AS Gets Positive Safety Review For 60 ?l/Kg Dose In Phase 2 ENACT Trial	RE
06-26	EXACT Therapeutics: Positive second safety read-out from the Phase 2 ENACT trial in pancreatic cancer	PU
06-26	EXACT Therapeutics Issues Positive Second Safety Read-Out From Phase 2 ENACT Trial In Pancreatic Cancer	CI
06-17	Euronext Oslo Børs Receives Exact Therapeutics' Delisting Application	MT
06-12	EXACT Therapeutics minutes from Annual General Meeting June 12, 2026	AQ
06-04	EXACT Therapeutics - webcast presentation	AQ
06-01	EXACT Therapeutics: Announces webcast regarding strategic intent to delist the company's shares from listing on Euronext Growth, Oslo	AQ
05-29	Exact Therapeutics' Board Proposes Delisting from Euronext Growth Oslo	MT
05-29	EXACT Therapeutics - Notice for Annual General Meeting 2026	AQ
05-29	EXACT Therapeutics: Strategic intent to delist the company's shares from listing on Euronext Growth, Oslo	AQ
04-09	EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-09	EXACT Therapeutics : Annual Report 2025	PU
03-26	EXACT Therapeutics AS: Share capital increase registered	AQ
03-13	EXACT Therapeutics AS - Minutes from extraordinary general meeting on 13 March 2026	AQ
03-13	EXACT Therapeutics : Notice of Extraordinary General Meeting for EXACT Therapeutics March 13, 2026	PU
03-03	Exact Therapeutics as Doses First Patient in Europe in Phase 2 Enact Trial for Locally Advanced Pancreatic Cancer	CI
03-03	EXACT Therapeutics : First patient dosed in Europe in Phase 2 trial in patients with locally advanced pancreatic cancer	PU
03-03	EXACT Therapeutics : First patient dosed in Europe in Phase 2 trial in patients with locally advanced pancreatic cancer	PU